skip to main | skip to sidebar

PharmCritic

Our mission is to provide information and news to encourage the pharmaceutical and medical industries to act in the public's interest by informing the public when they are not.

Showing posts with label avastin. Show all posts
Showing posts with label avastin. Show all posts

Monday, July 7, 2008

The dilemna of high cost and minimal benefit

The link below will take you to a New York Times article that discusses the cost and the benefits of Avastin. Avastin is a very expensive cancer drug.

The article does a good job of describing Avastin and the dilemna of having an expensive drug with limited benefits.

http://tinyurl.com/6443c5
Posted by Duncan at 4:52 PM No comments:
Labels: avastin, costly drug, limited benefits
Home
Subscribe to: Posts (Atom)

Blog Archive

  • ▼  2009 (3)
    • ▼  January (3)
      • FDA Scientist Complain to Obama about FDA corruption
      • The Politics of Marketing Gardasil
      • Fosomax-type drugs linked to jaw necrosis
  • ►  2008 (45)
    • ►  December (4)
    • ►  November (3)
    • ►  October (2)
    • ►  September (4)
    • ►  August (7)
    • ►  July (25)

About Me

United States
View my complete profile

Blogs and Sites

  • Scientific-misconduct- perceptive comments on scientific betrayers
  • Maggie Mahar's blog: very in depth, health policy, some pharma
  • Pharmamarketing- lots of original material, interesting perspectives
  • Pharmagossip-I visit everyday, from hard news to gossip
  • Bioethics Blog- some great stories